Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company focused on artificial intelligence (AI), went public in April ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Autonomous AI agents are more than just extensions of vendor tools. They’re credentialed actors who connect and execute, and ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

The healthcare industry generally takes a more cautious approach to the use of artificial intelligence, but it is happening. AI is being used to sift through massive amounts of digital data to provide ...

We recently published 10 Best Biotech Stocks to Buy Under $10. Recursion Pharmaceuticals, Inc. is placed eighth among them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage ...

Recursion could be on the verge of transforming the drug development process. However, the company has yet to demonstrate the superiority of its strategy. Moreover, Recursion is going to face growing ...

Recursion could be on the verge of transforming the drug development process. However, the company has yet to demonstrate the superiority of its strategy. Moreover, Recursion is going to face growing ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. This article is more than 4 years old. Chris Gibson, Co-Founder & CEO, Recursion ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...